It took a while, but I received a response from David Koos!
From: David R. Koos <dkoos@bmsn.us> To: lrahinsley@gmail.com Subject: Re: Regarding Bio-Matrix (BMSN) Content-Type: multipart/alternative; boundary=000e0cd2383e4b886b04a7de5ad6 Content-Type: text/plain; charset=windows-1252 Content-Transfer-Encoding: quoted-printable
Thank you for the E-Mail, Larry and I apologize for the delay. The board and I have decided for 2013 it would be best to merge Regen and Entest Bio into one company, Bio Matrix. However, they will continue to operate as Trade Names under the parent. We have submitted for release with Marketwire that we will begin clinical trials in 2013 for HemaXellerate. We have not yet given them the go ahead, but it will be released soon.
Thank you for your interest in Bio Matrix.
Warm Regards,
David R. Koos, PhD. Tel: 619-702-1404 Web: http://www.bmsn.us E-mail: dkoos@bmsn.us
Know where Everybody is Going & Get There First! Take any profit you can in Pink Land!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.